Rhythm Pharmaceuticals(NASDAQ) RYTM

Rhythm Pharmaceuticals, Inc. treats rare diseases causing extreme hunger. Its medicine, IMCIVREE, helps the brain manage appetite and weight. This therapy serves patients with specific genetic or brain conditions.

Solving Insatiable Hunger

• IMCIVREE Genetic Treatments: Precision medicine for Bardet-Biedl syndrome and genetic deficiencies; accounts for 72% of product revenue.
• Hypothalamic Obesity Therapy: Treatment for weight gain caused by brain injury; addresses hyperphagia, or pathological hunger, by targeting the melanocortin-4 receptor pathway.
• Global Market Operations: Sales activities in more than 25 countries outside the United States; accounts for 28% of product revenue.
• Next-Generation Pipeline: Development of weekly medicines and oral molecules for Prader-Willi syndrome and other rare neuroendocrine conditions.

Building Global Access

• Received FDA approval for acquired hypothalamic obesity on March 19, 2026.
• Obtained European Commission marketing authorization for hypothalamic obesity on April 30, 2026.
• Submitted a Japanese New Drug Application for setmelanotide in May 2026.
• Announced positive preliminary data from a Phase 2 trial for Prader-Willi syndrome on June 13, 2026.
• Announced preliminary data from a Phase 2 study of RM-718 in patients with acquired hypothalamic obesity on Aug. 4, 2026.

What Makes Rhythm Unique

Rhythm maintains a DNA database with 120,000 samples to support the diagnosis of rare genetic conditions. The company manages its own commercial infrastructure across the United States and several European markets.

Rhythm by the Numbers

• Total product revenue reached $71.3 million in the three-month period ended June 30, 2026, up 47% year over year.
• Net loss was $49.3 million for the three-month period ended June 30, 2026, compared to $46.6 million in the same period of 2025.
• Selling, general, and administrative expenses hit $67.4 million in the three-month period ended June 30, 2026, up 47% year over year.
• Cash, cash equivalents, and short-term investments totaled $330.9 million as of June 30, 2026.

The Path Ahead

Rhythm has evolved into a global commercial company with multiple approved indications for its lead therapy. Its focus on specific brain pathways allows for highly targeted treatments in rare neuroendocrine diseases.